Akeso (SZSC:9926) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

9926 주식 개요

바이오 제약 회사인 Akeso는 항체 의약품을 연구, 개발, 제조 및 상용화하는 회사입니다.

9926 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	2/6
과거 실적	4/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 55% 에서 거래

수익은 매년 9.05% 증가할 것으로 예상됩니다.

올해부터 흑자전환

분석가들은 주가가 65.5% 상승할 것이라는 데 동의합니다.

위험 분석

지난 1년 동안 주주가 희석되었습니다.

최근 3개월간 주가 변동성

Akeso, Inc. 경쟁사

Shanghai Henlius Biotech

SEHK:2696

HK$12.4b

Shanghai Haohai Biological Technology

SEHK:6826

HK$14.1b

3SBio

SEHK:1530

HK$15.2b

HBM Holdings

SEHK:2142

HK$1.0b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Akeso
과거 주가
현재 주가	HK$37.75
52주 최고치	HK$60.00
52주 최저치	HK$26.45
베타	0.45
11개월 변경	17.97%
3개월 변경 사항	-19.08%
1년 변경 사항	6.79%
33년 변화	-36.66%
5년 변화	n/a
IPO 이후 변화	0%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	9926	HK Biotechs	HK 마켓
7D	5.9%	-0.7%	-1.0%
1Y	6.8%	-34.6%	0.7%

수익률 대 산업: 9926 지난 1년 동안 -34.3 %를 반환한 Hong Kong Biotechs 산업을 초과했습니다.

수익률 대 시장: 9926 지난 1년 동안 2.5 %를 반환한 Hong Kong 시장을 초과했습니다.

가격 변동성

Is 9926's price volatile compared to industry and market?
9926 volatility
9926 Average Weekly Movement	14.3%
Biotechs Industry Average Movement	8.9%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	14.9%
10% least volatile stocks in HK Market	3.7%

안정적인 주가: 9926 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 9926 의 주간 변동성( 14% )은 지난 1년 동안 안정적이었지만 여전히 Hong Kong 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2012	2,778	Michelle Xia	www.akesobio.com

바이오 제약 회사인 아케소는 항체 의약품을 연구, 개발, 제조 및 상용화하는 회사입니다. 회사는 자궁경부암, 위암(GC), 위식도 접합부(GEJ) 암, 상피내암(ESCC), 간세포암(HCC), 소세포폐암(SCLC), 비소세포폐암(NSCLC), 췌장암 및 고형 종양 치료를 위한 PD-1/CTLA-4 이중 특이 항체인 AK104를 개발하고 있습니다; 비소세포폐암, 삼중음성유방암(TNBC), 두경부암, 간세포암, 대장암 및 난소암, 고형암 치료를 위한 PD-1/VEGF 이중특이항체 AK112를 개발 중입니다. 또한 골수형성이상증후군, 급성골수성백혈병, 위암, 전이성 위장관기질종양, 전이성 비소세포폐암, 비소세포폐암, 급성골수성백혈병, 고형암/림프종 치료를 위한 CD47 단일클론 항체 AK117을 개발 중입니다; 전형적인 호지킨 림프종(R/R cHL), 비소세포폐암, 비소세포폐암, 간세포암, 비소세포폐암, 갑상선암, 중피종 및 흉선암, ESCC, UC, GC, GEJ, 담관암, 신경내분비종양 및 불일치 복구 결핍 고형 종양 치료를 위한 PD-1 단일클론 항체인 AK105; 고형암 및 비소세포폐암 치료를 위한 CD73 단일클론항체 AK119, 위암, 간세포암, 간세포암 및 고형암 치료를 위한 VEGFR-2 단일클론항체 AK109.

Akeso, Inc. 기본 사항 요약

Akeso 의 수익과 매출은 시가총액과 어떻게 비교하나요?
9926 기본 통계
시가총액	HK$32.69b
수익(TTM)	HK$2.18b
수익(TTM)	HK$4.86b

15.0x

P/E 비율

6.7x

P/S 비율

9926 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
9926 손익 계산서(TTM)
수익	CN¥4.53b
수익 비용	CN¥137.51m
총 이익	CN¥4.39b
기타 비용	CN¥2.36b
수익	CN¥2.03b

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	2.34
총 마진	96.96%
순이익 마진	44.81%
부채/자본 비율	65.7%

9926 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

9926 주식 개요

보상

위험 분석

Akeso, Inc. 경쟁사

SEHK:2696

HK$12.4b

SEHK:6826

HK$14.1b

SEHK:1530

HK$15.2b

SEHK:2142

HK$1.0b

가격 내역 및 성능

최근 뉴스 및 업데이트

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

Recent updates

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

No longer forecast to breakeven

Full year 2022 earnings released: CN¥1.42 loss per share (vs CN¥1.32 loss in FY 2021)

Forecast to breakeven in 2023

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile

Forecast to breakeven in 2023

No longer forecast to breakeven

Less than half of directors are independent

Akeso, Inc. Announces Ivonescimab Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

No longer forecast to breakeven

Akeso's Ivonescimab (PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC

Akeso, Inc. Develops Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors

Akeso, Inc. Announces Commencement of Phase Ib/II clinical trial

Forecast to breakeven in 2024

Akeso, Inc. Publishes First Approval of Cadonilimab in Drugs, A Peer-Reviewed Medical Journal

Akeso, Inc. to Report First Half, 2022 Results on Aug 23, 2022

Akeso's Cadonilimab (Pd-1/Ctla-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China